Theravance Biopharma, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|
| Revenue | $15.4M | $48.6M | $42.1M | $11.7M | $226.0K | $130.1M |
| Cost of Revenue | $6.0M | $2.9M | $4.7M | $4.1M | $0 | $0 |
| Gross Profit | $9.4M | $45.8M | $37.5M | $7.6M | $226.0K | $130.1M |
| Gross Margin | 60.8% | 94.1% | 88.9% | 65.3% | 100.0% | 100.0% |
| Operating Expenses | ||||||
| Research & Development | $173.9M | $141.7M | $129.2M | $168.5M | $120.6M | $114.0M |
| SG&A Expense | $95.6M | $84.5M | $90.2M | $71.6M | $35.9M | $25.7M |
| Operating Income | $-260.1M | $-180.5M | $-181.9M | $-232.5M | $-156.3M | $-9.6M |
| Operating Margin | -1,690.6% | -371.0% | -431.8% | -1,989.6% | -69,152.2% | -7.4% |
| Interest Expense | $8.5M | $1.4M | $0 | $0 | — | — |
| Pretax Income | $-271.7M | $-180.6M | $-181.3M | $-230.7M | $-156.3M | $-9.6M |
| Income Tax Expense | $13.7M | $10.1M | $951.0K | $6.4M | $0 | $0 |
| Net Income | $-285.4M | $-190.7M | $-182.2M | $-237.0M | $-156.3M | $-9.6M |
| Net Margin | -1,855.0% | -391.9% | -432.6% | -2,028.0% | -69,152.2% | -7.4% |
| EPS (Basic) | $-5.45 | $-4.26 | $-5.34 | $-7.46 | $-4.92 | $-0.30 |
| EPS (Diluted) | $-5.45 | $-4.26 | $-5.34 | $-7.46 | $-4.92 | $-0.30 |
| Shares Outstanding (Basic) | 53.7M | 52.8M | 38.0M | 32.2M | 0 | — |
| Shares Outstanding (Diluted) | 52.4M | 52.8M | 38.0M | 32.2M | 0 | — |
| Dividends Per Share | — | — | — | — | — | — |